Melanotan II Research Evidence
The Melanotan II evidence base: trials, journals, and what the data does not yet show.
Key Findings at a Glance
• Melanotan II is a non-selective melanocortin receptor agonist that simultaneously affects pigmentation, sexual function, appetite, and inflammation through MC1R through MC5R activation. • Melanotan II produces UV-independent tanning by directly stimulating melanocytes to produce eumelanin, the protective dark pigment, without requiring sun exposure. • The sexual arousal effects observed with Melanotan II directly led to the development of PT-141, a more targeted derivative that became the first FDA-approved peptide for sexual dysfunction. • Melanotan II has a notably broad side effect profile including nausea and facial flushing precisely because it lacks selectivity and activates all five melanocortin receptor subtypes.
Sexual Function Effects
Extensive research demonstrates Melanotan II's pronounced pro-sexual effects through activation of melanocortin-3 and melanocortin-4 receptors (MC3R/MC4R) in hypothalamic nuclei controlling sexual behavior and arousal. Clinical studies in both men and women have documented increased spontaneous erections, enhanced libido, and improved sexual satisfaction scores following subcutaneous administration of the peptide. The sexual enhancement effects occur through central nervous system mechanisms independent of peripheral vascular changes, involving activation of oxytocinergic pathways and modulation of dopamine signaling in reward-related brain circuits. Research has shown onset of sexual function effects within 1-3 hours of administration, with duration of action extending up to 72 hours in some study subjects, making it distinct from fast-acting vasodilator treatments. These findings have positioned Melanotan II as an important research compound for investigating central regulation of sexual function, libido enhancement mechanisms, and the neurobiological connections between melanocortin signaling and sexual motivation pathways.
Fat Metabolism Effects
Emerging research suggests Melanotan II may influence fat metabolism through melanocortin receptor activation in both central and peripheral tissues, with studies documenting effects on lipolysis and adipocyte function. Animal research has shown MC4R activation increases sympathetic nervous system activity to adipose tissue, promoting fatty acid release and oxidation through enhanced beta-adrenergic signaling pathways. Studies indicate the peptide may preferentially affect visceral fat stores, which have higher melanocortin receptor expression than subcutaneous adipose depots, suggesting potential applications in abdominal fat reduction research. Research has documented increased energy expenditure and thermogenesis in treated animals, contributing to negative energy balance independent of appetite suppression effects. These fat metabolism optimization properties position Melanotan II as a research tool for investigating melanocortin-mediated metabolic regulation, body composition modification mechanisms, and the development of novel approaches to obesity and metabolic syndrome research.
Trials and reviews
- Wessells psychogenic ED crossover RCTJ Urol1998
double-blind placebo crossover · rigidity 38 min vs 3 min placebo · N=10
- Dorr dose-escalation pilotLife Sci1996
tanning response confirmed · safety-focused pilot · N=3
References
- Melanotan II: review of melanocortin agonist effects and risks · Habbema L, et al. · 2017
- Dorr RT, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences. 1996;58(20):1777-84. · King KM, Davis T · 1998
- Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. · Wessells H, Levine N, Hadley ME et al. · 2000
- Evaluation of melanotan-II, a superpotent cyclic melanotropic ... · Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME · 1996
- Wessells H, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. Journal of Urology. 1998;160(2):389-93. · Sabri O, Zimny M, Schreckenberger M, Reinartz P, Ostwald E, Buell U · 1999
- Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. · Wessells H, Gralnek D, Dorr R et al. · 2000
- Synthetic melanotropic peptide initiates erections in men ... - PubMed · Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N · 1998
- Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-30. · Quan N, Stern EL, Whiteside MB, Herkenham M · 1999
- [PDF] Edward Manookian Docket No. FDA-2015-N-4169 Page 2 · 2015
- Fan W, et al. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 1997;385(6612):165-8. · Holsboer F · 2000
- Melanotan II User Experience: A Qualitative Study of Online Discussion Forums. · Gilhooley E, Daly S, McKenna D · 2021
- Melanotan II: a possible cause of renal infarction - PubMed · Peters B, Hadimeri H, Wahlberg R, Afghahi H · 2020
- Brennan R, et al. Melanotan II: a review of the evidence for efficacy and safety. Dermatology Online Journal. 2019. · Yarosh DB · 2019